ReproNovo is a biopharmaceutical company dedicated to developing innovative treatments for reproductive medicine. Headquartered in Lausanne, Switzerland, the company maintains primary development operations in Copenhagen, Denmark, and an additional site in Barcelona, Spain. It is backed by prominent life sciences investors.
Subscribe to see ReproNovo’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
ReproNovo is a drug discovery company headquartered in Lausanne, Switzerland. Its most recent funding round, Series A, raised $65M in May 2025. Xcout tracks 21 named people at ReproNovo, including Jean Marie Duvall (Chief Executive Officer).
As of 16 November 2026. Source: Xcout Intel.
15 more named people on record for ReproNovo, with roles, board committees and tenure — see the full roster →
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Series A | $65M | 5 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
A few of ReproNovo's closest competitors — see the full list of competitors and alternatives →
MinervaX is a privately held biotechnology company headquartered in Copenhagen, Denmark, pursuing the development of a novel maternal prophylactic vaccine for the prevention of Group B Streptococcus disease.
LUCA Science is a pre-clinical stage biotechnology company that develops functional mitochondria as therapeutic agents to treat damaged tissues and organs. The company utilizes a proprietary method to isolate functional mitochondria, combining it with advanced drug delivery and formulation technology to create storable biopharmaceutical agents.
Kainova Therapeutics, formerly known as Domain Therapeutics, is a clinical-stage biopharmaceutical company headquartered in Montreal, Quebec. The company drives a clinical pipeline of advanced GPCR-modulating therapies to address unmet medical needs.
Immitra Bio GmbH is a biotechnology startup and ETH Zürich spin-off developing a scalable in-vivo genetic medicine platform to treat rare genetic diseases. Headquartered in Schlieren, Switzerland, the company secured early-stage venture funding to advance its gene-editing therapies.
Retro Biosciences is a biotechnology research company based in Redwood City, California, that develops therapies targeting aging biology. Its goal is to extend healthy human lifespan by 10 years.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about ReproNovo? Suggest a correction · Work at ReproNovo? Claim this profile
Post the link and the card appears automatically — each network fetches the image itself.